Bone Marrow Transplantation News

Prophylactic treatment with low-dose corticosteroids accelerated platelet recovery and significantly decreased the prevalence of acute graft-versus-host disease among high-risk patients undergoing haploidentical hematopoietic stem cell transplantation, according to the results of an open-label, randomized control trial.

Cancer treatment centers in the United States spent $173 million on advertising in the year 2014, according to a research letter published in JAMA Internal Medicine.

ASH announced seven recipients of the 2016 ASH Research Training Award for Fellows, a yearlong program designed to encourage careers in academic hematology by providing protected research during training.

The FDA approved dronabinol oral solution for the treatment of patients with cancer who experience chemotherapy-induced nausea and vomiting, according to a press release from the agent’s manufacturer.

Fox Chase Cancer Center announced two staff appoints.

Short sleep duration and frequent snoring prior to cancer diagnosis may shorten OS among postmenopausal women with breast cancer.

PHILADELPHIA — Fox Chase Cancer Center today hosted a Regional Cancer Moonshot Summit in conjunction with the National Cancer Moonshot Summit held in Washington, D.C., marking the first time that stakeholders representing all cancer types convened under one national charge.

Nancy E. Davidson, MD, director of University of Pittsburgh Cancer Institute, took over as president of the American Association for Cancer Research this spring.

The FDA today granted breakthrough therapy designation to ibrutinib as a monotherapy treatment for chronic graft-versus-host disease after failure of one or more lines of systemic therapy.

Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation, has been named acting director of the agency’s new Oncology Center of Excellence.